B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23029IDB-L5

Select Item

Empower your strategies with our B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions.

B-cell acute lymphocytic leukemia (B-Cell ALL), also known as B-cell acute lymphoblastic leukemia, is a type of blood cancer that originates in the bone marrow and affects B-cell lymphocytes, a type of white blood cell. In B-cell ALL, these immature B cells undergo malignant transformation, leading to the rapid production of abnormal lymphoblasts. These abnormal cells can crowd out normal blood cells, leading to symptoms such as fatigue, anemia, increased susceptibility to infections, and bleeding. B-cell ALL is most commonly diagnosed in children but can affect adults as well. Treatment typically includes chemotherapy, targeted therapies, stem cell transplantation, and sometimes radiation therapy. The goal is to induce remission and eliminate cancer cells from the bone marrow. Advances in treatment have improved the prognosis for many patients with B-cell ALL.

The B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) drugs in development market research report provide comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Key Targets
· B Lymphocyte Antigen CD19; B Cell Receptor CD22; CD3 ; B Lymphocyte Antigen CD20; Interleukin 3 Receptor Subunit Alpha; Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1; Apoptosis Regulator Bcl 2; Fc Fragment Of IgG Low Affinity III Receptor; ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1; and Caspase
Key Mechanisms of Action
· CD3 Agonist; B Lymphocyte Antigen CD19 Inhibitor; Interleukin 3 Receptor Subunit Alpha Antagonist; Apoptosis Regulator Bcl 2 Inhibitor; Asparagine Depletor; Caspase Activator; Serine/Threonine Protein Kinase mTOR Inhibitor; T Cell Specific Surface Glycoprotein CD28 Agonist; T Cell Surface Glycoprotein CD3 Epsilon Chain Agonist; and Programmed Cell Death 1 Ligand 1 Inhibitor
Key Routes of Administration
· Intravenous; Parenteral; Oral; Subcutaneous; Intramuscular; Intratumor; and Intravenous Drip
Key Molecule Types
· Gene-Modified Cell Therapy; Monoclonal Antibody; Small Molecule; Monoclonal Antibody Conjugated; Cell Therapy; Recombinant Enzyme; Recombinant Protein; Oligonucleotide; Biologic; and Gene Therapy
Major Companies
· Hebei Senlang Biotechnology Co Ltd; Wellington Zhaotai Therapies Ltd; Novartis AG; Gracell Biotechnologies Inc; Beijing Boren Hospital; Autolus Therapeutics Plc; Chongqing Precision Biotech Co Ltd; Nanjing Bioheng Biotech Co Ltd; Pfizer Inc; and Orca Biosystems Inc

Scope

  • Therapeutics in Development: Covering 212 molecules, with 151 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Abclon Inc
Achelois BioPharma Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Amgen Inc
Anhui Provincial Hospital of Chinese Medicine
Arovella Therapeutics Ltd
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Athenex Inc
Autolus Therapeutics Plc
Auxi Therapeutics Sdn Bhd
Avalon GloboCare Corp
AVM Biotechnology LLC
Bambino Gesu Hospital and Research Institute
Beijing Boren Hospital
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Tongren Hospital
Bellicum Pharmaceuticals Inc
Bioceltech Therapeutics Ltd
Biohaven Ltd
BRL Medicine Inc
Capital Medical University
CARGO Therapeutics Inc
Cellectis SA
Cellex Gesellschaft fur Zellgewinnung mbH
Century Therapeutics Inc
Ceptur Therapeutics Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu USino Technology Biology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Children’s Hospital of Fudan University
China Immunotech (Beijing) Biotechnology Co Ltd
China Immunotech Co Ltd
Chongqing Precision Biotech Co Ltd
City of Hope
CoImmune Inc
CRISPR Therapeutics AG
Cullinan Oncology Inc
Curon Biopharmaceutical Ltd
CytoCares Shanghai Inc
Dalian Medical University
Dmitry Rogachev National Research Center of Pediatric Hematology
Oncology and Immunology
EdiGene Inc
Elf Zone Inc
Enzyme by Design Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fochon Pharmaceutical Ltd
Fosun Kite Biotechnology Co Ltd
Gansu Provincial Cancer Hospital
Genenta Science SpA
Genentech USA Inc
General Hospital of the People's Liberation Army
Generium
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangdong Second Provincial General Hospital
Guangdong Zhaotai Cell Biotechnology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Qihan Biotechnology Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hebei Yanda Hospital
Henan Cancer Hospital
Henan Honghui Biotechnology Co Ltd
HRAIN Biotechnology Co Ltd
Huadao Shanghai Biomedical Co Ltd
iCell Gene Therapeutics LLC
Immuneel Therapeutics Pvt Ltd
Immunotech Biopharm Ltd
Imugene Ltd
Innate Pharma SA
Institute of Hematology and Blood Transfusion
ITabMed Co Ltd
Jenthera Therapeutics Inc
Jilin University
Johnson & Johnson
Juventas Cell Therapy Ltd
JW Cayman Therapeutics Co Ltd
Kecellitics Biotech Co Ltd
KK Women's and Children's Hospital
Kunming Medical University
Legend Biotech Corp
Leman Biotech Co Ltd
Les Laboratoires Servier SAS
Loyola University Chicago
Luoyang Central Hospital
MacroGenics Inc
ManysmarT Therapeutics Inc
Maru Therapeutics Co Ltd
Miltenyi Biomedicine GmbH
Nagoya University Hospital
Nanfang Hospital
Nanfang Hospital of Southern Medical University
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
National University of Malaysia
Nationwide Children's Hospital
Navy General Hospital
Nektar Therapeutics
Newave Pharmaceutical Inc
Nkarta Inc
Novartis AG
NovoMedix LLC
Ohio State University Comprehensive Cancer Center
OneChain Immunotherapeutics
Orca Biosystems Inc
Orgenesis Inc
Oslo University Hospital
PeproMene Bio Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Precigen Inc
Puretech Health Plc
Saban Research Institute of Childrens Hospital Los Angeles
Second Affiliated Hospital of Shanxi Medical University
Shandong University
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Jiao Tong University School of Medicine
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pudong Hospital
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Pregene Biopharma Co Ltd
Shenzhen Second People's Hospital
Shenzhen University General Hospital
Sichuan University
SinoCelltech Group Ltd
SooChow University
Stanford University
Sunnycell Therapeutics Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Systimmune Inc
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Tianjin Mycure Medical Technology Co Ltd
University of Colorado Denver
University of Minnesota
University of Sao Paulo
University of Texas MD Anderson Cancer Center
Vincerx Pharma Inc
Vinmec Research Institute of Stem Cell and Gene Technology
Wellington Zhaotai Therapies Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Xiamen Nuokang Biotechnology Co Ltd
Xuanwu Hospital Capital Medical University
Xuzhou Medical University
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang University
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 in real time.

  • Access a live B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more